BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2467912)

  • 21. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
    Pöllänen J; Saksela O; Salonen EM; Andreasen P; Nielsen L; Danø K; Vaheri A
    J Cell Biol; 1987 Apr; 104(4):1085-96. PubMed ID: 3104349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
    Seiffert D; Mimuro J; Schleef RR; Loskutoff DJ
    Cell Differ Dev; 1990 Dec; 32(3):287-92. PubMed ID: 1711915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
    Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
    Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
    Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
    Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
    Bruckner A; Filderman AE; Kirchheimer JC; Binder BR; Remold HG
    Cancer Res; 1992 Jun; 52(11):3043-7. PubMed ID: 1375533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
    Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
    J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator.
    Hekman CM; Loskutoff DJ
    Arch Biochem Biophys; 1988 Apr; 262(1):199-210. PubMed ID: 3128176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of a plasminogen activator and its inhibitor in human mesangial cells.
    Lacave R; Rondeau E; Ochi S; Delarue F; Schleuning WD; Sraer JD
    Kidney Int; 1989 Mar; 35(3):806-11. PubMed ID: 2496257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
    Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
    J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
    Gyetko MR; Webb AC; Sitrin RG
    J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
    Ehrlich HJ; Keijer J; Preissner KT; Gebbink RK; Pannekoek H
    Biochemistry; 1991 Jan; 30(4):1021-8. PubMed ID: 1703436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinases and cellular fibrinolytic activity.
    Lijnen HR
    Biochemistry (Mosc); 2002 Jan; 67(1):92-8. PubMed ID: 11841344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
    Lawrence D; Strandberg L; Grundström T; Ny T
    Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity.
    Boncela J; Papiewska I; Fijalkowska I; Walkowiak B; Cierniewski CS
    J Biol Chem; 2001 Sep; 276(38):35305-11. PubMed ID: 11418606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
    Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
    J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
    Praus M; Collen D; Gerard RD
    Int J Cancer; 2002 Dec; 102(6):584-91. PubMed ID: 12447999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract.
    Radtke KP; Wenz KH; Heimburger N
    Biol Chem Hoppe Seyler; 1990 Dec; 371(12):1119-27. PubMed ID: 1708670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.